BrightPath Biotherapeutics Co., Ltd. Reports Consolidated and Non-Consolidated Earnings Results for the Year Ended March 31, 2018; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2019
May 11, 2018 at 03:05 am EDT
Share
BrightPath Biotherapeutics Co., Ltd. reported consolidated and non-consolidated earnings results for the year ended March 31, 2018. For the year, on consolidated basis, the company reported net sales of JPY 354 million against JPY 529 million a year ago. Operating loss was JPY 1,561 million against JPY 1,113 million a year ago. Ordinary loss was JPY 1,573 million against JPY 1,113 million a year ago. Loss attributable to owners of parent was JPY 1,577 million or JPY 41.25 per share against JPY 1,113 million or JPY 32.74 per share a year ago. Loss before income taxes was JPY 1,573,292,000 against JPY 1,116,928,000 a year ago. Net cash used in operating activities was JPY 1,591,336,000 against JPY 1,067,512,000 a year ago. Purchase of property, plant and equipment was JPY 108,218,000 against JPY 97,237,000 a year ago. Purchase of intangible assets was JPY 3,337,000 against JPY 6,605,000 a year ago. Negative return on shareholders' equity was 26.1% against 28.2% a year ago.
For the year, on non-consolidated basis, the company reported net sales of JPY 354 million against JPY 529 million a year ago. Operating loss was JPY 1,452 million against JPY 1,094 million a year ago. Ordinary loss was JPY 1,569 million against JPY 1,089 million a year ago. Net loss was JPY 1,577 million or JPY 41.25 per share against JPY 1,113 million or JPY 32.74 per share a year ago.
For the year ending March 31, 2019, on consolidated basis, the company expects net sales of JPY 150 million, operating loss of JPY 2,200 million, ordinary loss of JPY 2,200 million and loss attributable to owners of parents of JPY 2,200 million or JPY 52.59 per share.
BrightPath Biotherapeutics Co., Ltd. is a Japan-based company mainly engaged in the development of pharmaceutical products. The Company is a biopharmaceutical venture company focused on developing cancer immunotherapeutic. The Companies business model covers drug discovery research and early clinical development of cancer immunotherapy; conducting of early-phase clinical trials; and development, manufacturing, and launching of the drugs as commercial products in Japan and abroad. The Company also generates the revenues from license fees from the pharmaceutical companies.
BrightPath Biotherapeutics Co., Ltd. Reports Consolidated and Non-Consolidated Earnings Results for the Year Ended March 31, 2018; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2019